Literature DB >> 30664675

Potential treatment strategy for NASH.

Alan Morris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30664675     DOI： 10.1038/s41574-019-0162-1

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.

Authors:  Arun Sanyal; Edgar D Charles; Brent A Neuschwander-Tetri; Rohit Loomba; Stephen A Harrison; Manal F Abdelmalek; Eric J Lawitz; Dina Halegoua-DeMarzio; Sudeep Kundu; Stephanie Noviello; Yi Luo; Rose Christian
Journal:  Lancet       Date:  2018-12-13       Impact factor: 79.321
  1 in total
  2 in total

1.  Fat mass and obesity-associated protein promotes liver steatosis by targeting PPARα.

Authors:  Xiaohui Wei; Jielei Zhang; Min Tang; Xuejiao Wang; Nengguang Fan; Yongde Peng
Journal:  Lipids Health Dis       Date:  2022-03-13       Impact factor: 3.876

2.  Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects.

Authors:  Kaori Nakanishi; Chisaki Ishibashi; Seiko Ide; Ryohei Yamamoto; Makoto Nishida; Izumi Nagatomo; Toshiki Moriyama; Keiko Yamauchi-Takihara
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.